Inga U.
- Country
- Denmark
- Department
- Neurologisk Afdeling
Research Overview
- Evaluation of Ocrelizumab Efficacy and Safety in Multiple Sclerosis Patients from a Prior Phase IIIb/IV Trial
- Evaluation of Efficacy, Safety, and Pharmacokinetics of Increased Ocrelizumab Dose in Adults with Primary Progressive Multiple Sclerosis
- Non-Inferiority Trial of Ocrelizumab Versus Rituximab in Active Multiple Sclerosis Patients
Data & Insights
Has run more than one trial at 16 of 101 partner sites.
Specializations
Neurological Disorders
This investigator specializes in the treatment and research of multiple sclerosis (MS), with particular emphasis on advancing therapeutic approaches for various forms of the condition.
- Primary Progressive Multiple Sclerosis (PPMS)
- Active Multiple Sclerosis Management
- Advanced Treatment Protocols
The investigator evaluates novel therapeutic interventions for MS patients, focusing on disease progression and treatment effectiveness.
Therapeutic Innovation
Expertise in comparing and evaluating disease-modifying therapies for multiple sclerosis, particularly focusing on targeted biological treatments.
- Comparative Treatment Studies
- Long-term Treatment Outcomes
- Extended Interval Dosing Strategies
The investigator explores optimized treatment protocols and innovative dosing approaches for enhanced patient outcomes.
Clinical Assessment
Focuses on evaluating disability progression and treatment effectiveness in multiple sclerosis patients through comprehensive clinical assessment.
- Disease Progression Monitoring
- Treatment Response Assessment
- White Matter Lesion Analysis
The investigator utilizes advanced clinical metrics to assess therapeutic efficacy and disease status.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.